1N9 Stock Overview
Develops and markets nutraceutical products in Canada, Germany, and Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NeutriSci International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.01 |
| 52 Week Low | CA$0.0005 |
| Beta | 0.84 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | -99.33% |
| 5 Year Change | -98.66% |
| Change since IPO | -99.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1N9 | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 0.2% |
| 1Y | 0% | -6.0% | 8.5% |
Return vs Industry: 1N9 underperformed the German Personal Products industry which returned 3.6% over the past year.
Return vs Market: 1N9 exceeded the German Market which returned -1.3% over the past year.
Price Volatility
| 1N9 volatility | |
|---|---|
| 1N9 Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 3.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 1N9's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 1N9's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Glen Rehman | www.neutrisci.com |
NeutriSci International Inc. develops and markets nutraceutical products in Canada, Germany, and Japan. It offers neuenergy, an energy tab designed to deliver enhanced focus and mental clarity. The company sells its products through a distribution network of retail storefront and online markets.
NeutriSci International Inc. Fundamentals Summary
| 1N9 fundamental statistics | |
|---|---|
| Market cap | €589.65k |
| Earnings (TTM) | -€365.14k |
| Revenue (TTM) | €39.65k |
14.9x
P/S Ratio-1.6x
P/E RatioIs 1N9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1N9 income statement (TTM) | |
|---|---|
| Revenue | CA$59.98k |
| Cost of Revenue | CA$145.85k |
| Gross Profit | -CA$85.86k |
| Other Expenses | CA$466.59k |
| Earnings | -CA$552.45k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0031 |
| Gross Margin | -143.15% |
| Net Profit Margin | -921.00% |
| Debt/Equity Ratio | -23.2% |
How did 1N9 perform over the long term?
See historical performance and comparison